ReviewCurrent topics in medicinal chemistry2014
Radiosyntheses using fluorine-18: the art and science of late stage fluorination.
Review in Current topics in medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- The influence of functional groups and their relative position on isotopic exchange betweenEJNMMI radiopharmacy and chemistry · 2026Article
- Versatile Pyridinium Trifluoroborate Platform for Facile Preparation ofACS central science · 2026Article
- Advancing Positron Imaging with Alginate-Based Tracers: Design, Synthesis, and Radiolabelling Methods.MethodsX · 2026Article
- Article
- Trifluoromethylation of alkyl electrophiles withScience (New York, N.Y.) · 2025Article
- A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging.Molecules (Basel, Switzerland) · 2025Review
- From Inhibitors to PET: SAR-Based Development of [Journal of medicinal chemistry · 2025Article
- Arene and Heteroarene Functionalization Enabled by Organic Photoredox Catalysis.Accounts of chemical research · 2025Article
- PET in the characterization of immune diseases and development of therapeutics.Oxford open immunology · 2025Review
- The [18F] F-PSMA Probe: Chemical Perspectives.Current medicinal chemistry · 2025Review
- An ACE2 PET imaging agent derived fromEJNMMI radiopharmacy and chemistry · 2024Article
- C-H Labeling with [ACS central science · 2024Review
- A versatile fluorinated azamacrocyclic chelator enablingChemical science · 2024Article
- Manufacturing 6-[Organic letters · 2024Article
- Development of High-Throughput Experimentation Approaches for Rapid Radiochemical Exploration.Journal of the American Chemical Society · 2024Article
- Synthesis and Characterization of a New Carbon-11 Labeled Positron Emission Tomography Radiotracer for Orexin 2 Receptors Neuroimaging.Drug design, development and therapy · 2024Article
- Photo-activatable Reagents for Bioorthogonal Ligation Reactions.Topics in current chemistry (Cham) · 2023Review
- OMNI: Gas Chromatograph Captures Seven Common PET Radiotracer Analytes in under 5 Minutes.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [Journal of the American Chemical Society · 2023Article
- Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors.Pharmaceutics · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Positron (β(+)) emission tomography (PET) is a powerful, noninvasive tool for the in vivo, three-dimensional imaging of physiological structures and biochemical pathways. The continued growth of PET imaging relies on a corresponding increase in access to radiopharmaceuticals (biologically active molecules labeled with short-lived radionuclides such as fluorine-18). This unique need to incorporate the short-lived fluorine-18 atom (t1/2 = 109.77 min) as late in the synthetic pathway as possible has made development of methodologies that enable rapid and efficient late stage fluorination an area of research within its own right. In this review we describe strategies for radiolabeling with fluorine-18, including classical fluorine-18 radiochemistry and emerging techniques for late stage fluorination reactions, as well as labeling technologies such as microfluidics and solid-phase radiochemistry. The utility of fluorine-18 labeled radiopharmaceuticals is showcased through recent applications of PET imaging in the healthcare, personalized medicine and drug discovery settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.